特发性非感染性葡萄膜炎患者青光眼风险:多机构真实世界回顾性队列研究
该回顾性队列研究基于美国多机构 federated 研究网络 2006–2024 年数据,经倾向评分匹配后纳入非感染性葡萄膜炎与对照各 16,910 例成人患者。非感染性葡萄膜炎患者新发青光眼风险约为对照的 10 倍(HR 9.63,95%CI 7.75–11.95),随访第一年风险最高(HR 33.78,95%CI 19.02–59.90),全葡萄膜炎与 18–49 岁组风险突出。
要点
- 非感染性葡萄膜炎患者新发青光眼风险显著升高(HR 9.63,95%CI 7.75–11.95)。
- 随访第一年风险最高(HR 33.78),全葡萄膜炎风险最大(HR 50.49)。
- 18–49 岁组风险显著升高(HR 36.65),全身与眼科糖皮质激素使用均与风险升高相关。
核心结论
- 非感染性葡萄膜炎是青光眼的显著危险因素,年轻成人、全葡萄膜炎患者及诊断后第一年风险最高。
- 研究提示需按风险分层进行青光眼监测以预防不可逆视力丧失。
研究设计与样本
- 纳入成人非感染性葡萄膜炎患者并排除系统性自身免疫病,按年龄、性别、种族、合并症及用药 1:1 倾向评分匹配后两组各 16,910 例。
- 暴露为非感染性葡萄膜炎诊断,主要结局为索引日期后经 ICD-10-CM 编码识别的新发青光眼诊断。
- 采用眼科就诊对照组的敏感性分析以处理潜在监测偏倚。
主要发现
- 非感染性葡萄膜炎患者新发青光眼风险较对照升高近 10 倍(HR 9.63;95%CI 7.75–11.95)。
- 敏感性分析中风险仍稳健(HR 7.11;95%CI 6.21–8.15)。
- 随访第一年风险最高(HR 33.78;95%CI 19.02–59.90)。
- 多数亚型风险显著:原发性开角型青光眼 HR 4.47(95%CI 3.50–5.69),原发性闭角型青光眼 HR 11.55(95%CI 5.60–23.82),药物性青光眼 HR 51.29(95%CI 16.35–160.00)。
- 葡萄膜炎亚型中全葡萄膜炎风险最大(HR 50.49;95%CI 22.36–113.00);18–49 岁组 HR 36.65(95%CI 18.14–74.00);全身糖皮质激素 HR 10.19(95%CI 6.34–16.37),眼科糖皮质激素 HR 5.67(95%CI 3.88–8.30)。
关键数值与推荐
- 非感染性葡萄膜炎患者新发青光眼风险 HR 9.63(95%CI 7.75–11.95)。
- 随访第一年 HR 33.78(95%CI 19.02–59.90)。
- 全葡萄膜炎 HR 50.49(95%CI 22.36–113.00)。
- 18–49 岁组 HR 36.65(95%CI 18.14–74.00)。
- 全身糖皮质激素使用 HR 10.19(95%CI 6.34–16.37),眼科糖皮质激素使用 HR 5.67(95%CI 3.88–8.30)。
临床怎么用
- 对非感染性葡萄膜炎患者,尤其是年轻成人、全葡萄膜炎及诊断后第一年,应加强青光眼监测。
- 使用全身或眼科糖皮质激素时需警惕青光眼风险升高,并纳入风险分层随访。
局限性
- 回顾性队列设计,青光眼诊断依赖 ICD-10-CM 编码,可能存在误分类。
- 采用眼科就诊对照组的敏感性分析处理监测偏倚,但残余偏倚不能排除。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the risk of developing glaucoma following a diagnosis of idiopathic noninfectious uveitis and to stratify this risk by uveitis subtype, patient demographics, and corticosteroid use. DESIGN: Retrospective cohort study using data from January 1, 2006, to December 31, 2024. PARTICIPANTS: Adult patients with noninfectious uveitis were identified within a multi-institutional US collaborative federated research network. Patients with systemic autoimmune diseases were excluded to isolate ocular inflammation risk. After 1:1 propensity score matching for age, sex, race, comorbidities, and medication use, two balanced cohorts of 16,910 patients each were established. METHOD: The exposure was a diagnosis of noninfectious uveitis. Patients were followed for the development of new glaucoma diagnoses, identified using ICD-10-CM codes. A sensitivity analysis using an ophthalmology encounters control group was performed to address potential surveillance bias. MAIN OUTCOME MEASURES: The primary outcome was the incidence of a new glaucoma diagnosis after the index date, identified by ICD-10-CM codes. RESULTS: Patients with noninfectious uveitis had a nearly 10-fold increased risk of developing glaucoma compared to controls (hazard ratio [HR], 9.63; 95% CI, 7.75-11.95). This risk remained robust in the sensitivity analysis (HR, 7.11; 95% CI, 6.21-8.15). The risk was highest during the first follow-up year (HR, 33.78; 95% CI, 19.02-59.90), and was significant across most subtypes, including primary open-angle glaucoma (HR, 4.47; 95% CI, 3.50-5.69), primary angle-closure glaucoma (HR, 11.55; 95% CI, 5.60-23.82), and drug-induced glaucoma (HR, 51.29; 95% CI, 16.35-160.00). Among uveitis subtypes, panuveitis was associated with the greatest risk (HR, 50.49; 95% CI, 22.36-113.00). Stratified analyses showed a markedly elevated uveitis risk for glaucoma in the youngest age group (18-49 years: HR, 36.65; 95% CI, 18.14-74.00). Both systemic (HR, 10.19; 95% CI, 6.34-16.37) and ophthalmic (HR, 5.67; 95% CI, 3.88-8.30) corticosteroid use were associated with increased uveitis risk for glaucoma. CONCLUSIONS: Noninfectious uveitis is a significant risk factor for glaucoma, with the highest risk observed in younger adults, panuveitis patients, and during the first year after diagnosis. These findings underscore the need for a risk-stratified glaucoma surveillance to prevent irreversible vision loss.
引用
- Liu DY, Kuo HT, Hsu AY, et al. Risk of Glaucoma in Patients With Idiopathic Noninfectious Uveitis: A Multi-Institutional Real-World Retrospective Cohort Study. Am J Ophthalmol. 2026. PMID: 41592690. doi:10.1016/j.ajo.2026.01.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。